Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780539) titled 'Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors' on Aug. 19.

Study Type: Observational

Primary Sponsor: Yefeng

Condition: Neuroendocrine (NE) Tumors

Intervention: Drug: Surufatinib Administration

Recruitment Status: Not recruiting

Date of First Enrollment: September 1, 2026

Target Sample Size: 60

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07780539

Disclaimer: Curated by HT Syndication....